p.94 抽出テキスト

Kusumoto et al 2018 Bradycardia Clinical Practice Guidelines

Circulation. 2019;140:e382–e482. DOI: 10.1161/CIR.0000000000000628 August 20, 2019 e475 CLINICAL STATEMENTS AND GUIDELINES

S8.1.2.5.2-16.	 Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. JAMA Cardiol. 2016;1:324–32. S8.1.2.5.2-17.	 Chang SM, Nagueh SF, Spencer WH 3rd, et al. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42:296–300. S8.1.2.5.2-18.	 Fitzgerald P, Kusumoto F. The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system. J Interv Card Electrophysiol. 2018;52:403–8. S8.1.2.5.2-19.	 Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e272–391. S8.1.2.5.2-20.	 Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470–6. S8.1.2.5.2-21.	 Schuller JL, Zipse MM, Krantz MJ, et al. Incidence and predic-

tors of late complete heart block after alcohol septal ablation treatment of hypertrophic obstructive cardiomyopathy. J Interv Cardiol. 2015;28:90–7.

8.1.2.6 Managing Episodes of Bradycardia Associated With Postoperative AF

S8.1.2.6-1.	 Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med. 2001;135:1061–73. S8.1.2.6-2.	 Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016;374:1911–21. S8.1.2.6-3.	 Levine SA, Miller H, Penton GB. Some clinical features of complete heart block. Circulation. 1956;13:801–24. S8.1.2.6-4.	 Echahidi N, Pibarot P, O’Hara G, et al. Mechanisms, prevention,

and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51:793–801.

8.2 Bradycardia Management for Adult

Congenital Heart Disease

S8.2-1.	 Albin G, Hayes DL, Holmes DR Jr. Sinus node dysfunction in pediatric and young adult patients: treatment by implantation of a permanent pacemaker in 39 cases. Mayo Clin Proc. 1985;60:667–72. S8.2-2.	 Diller GP, Dimopoulos K, Okonko D, et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll Cardiol. 2006;48:1250–6. S8.2-3.	 Fishberger SB, Wernovsky G, Gentles TL, et al. Factors that influence the development of atrial flutter after the Fontan operation. J Thorac Cardiovasc Surg. 1997;113:80–6. S8.2-4.	 Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997;29:194–201. S8.2-5.	 Helbing WA, Hansen B, Ottenkamp J, et al. Long-term results of atrial correction for transposition of the great arteries. Comparison of Mustard and Senning operations. J Thorac Cardiovasc Surg. 1994;108:363–72. S8.2-6.	 Sanders P, Morton JB, Kistler PM, et al. Electrophysiological and electroanatomic characterization of the atria in sinus node disease: evidence of diffuse atrial remodeling. Circulation. 2004;109:1514–22. S8.2-7.	 Connelly MS, Liu PP, Williams WG, et al. Congenitally corrected transposition of the great arteries in the adult: functional status and complications. J Am Coll Cardiol. 1996;27:1238–43. S8.2-8.	 Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term

outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255–61. S8.2-9.	 Lundstrom U, Bull C, Wyse RK, et al. The natural and “unnatu-

ral” history of congenitally corrected transposition. Am J Cardiol. 1990;65:1222–9. S8.2-10.	 Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med. 1987;316:835–9. S8.2-11.	 Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation. 1995;92:442–9. S8.2-12.	 Glikson M, Dearani JA, Hyberger LK, et al. Indications, effectiveness, and long-term dependency in permanent pacing after cardiac surgery. Am J Cardiol. 1997;80:1309–13. S8.2-13.	 Kim MH, Deeb GM, Eagle KA, et al. Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. Am J Cardiol. 2001;87:649–51; a10. S8.2-14.	 Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol. 1995;18:1005–S8; 2-16. S8.2-15.	 Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol. 2003;92:871–6. S8.2-16.	 Janousek J, Paul T, Luhmer I, et al. Atrial baffle procedures for complete transposition of the great arteries: natural course of sinus node dysfunction and risk factors for dysrhythmias and sudden death. Z Kardiol. 1994;83:933–8. S8.2-17.	 DeSimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation. 2013;128:1433–41. S8.2-18.	 Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation. 2006;113:2391–7. S8.2-19.	 Silvetti MS, Drago F, Rava L. Long-term outcome of transvenous bipolar atrial leads implanted in children and young adults with congenital heart disease. Europace. 2012;14:1002–7. S8.2-20.	 Gillette PC, Wampler DG, Shannon C, et al. Use of atrial pacing in a young population. Pacing Clin Electrophysiol. 1985;8: 94–100. S8.2-21.	 Silvetti MS, Drago F, Marcora S, et al. Outcome of single-chamber, ventricular pacemakers with transvenous leads implanted in children. Europace. 2007;9:894–9. S8.2-22.	 Abu-El-Haija B, Bhave PD, Campbell DN, et al. Venous stenosis after transvenous lead placement: a study of outcomes and risk factors in 212 consecutive patients. J Am Heart Assoc. 2015;4:e001878. S8.2-23.	 Emmel M, Sreeram N, Brockmeier K, et al. Superior vena cava stenting and transvenous pacemaker implantation (stent and pace) after the Mustard operation. Clin Res Cardiol. 2007;96:17–22. S8.2-24.	 Karpawich PP, Gillette PC, Garson A Jr, et al. Congenital complete atrioventricular block: clinical and electrophysiologic predictors of need for pacemaker insertion. Am J Cardiol. 1981;48:1098–102. S8.2-25.	 Murray LE, Smith AH, Flack EC, et al. Genotypic and phenotypic predictors of complete heart block and recovery of conduction after surgical repair of congenital heart disease. Heart Rhythm. 2017;14:402–9. S8.2-26.	 McLeod CJ, Attenhofer Jost CH, Warnes CA, et al. Epicardial versus endocardial permanent pacing in adults with congenital heart disease. J Interv Card Electrophysiol. 2010;28:235–43. S8.2-27.	 Walker F, Siu SC, Woods S, et al. Long-term outcomes of cardiac pacing in adults with congenital heart disease. J Am Coll Cardiol. 2004;43:1894–901. S8.2-28.	 Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503–51. S8.2-29.	 Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm. 2017;14:e97–153. S8.2-30.	 Padmanabhan D, Kella DK, Mehta R, et al. Safety of magnetic resonance imaging in patients with legacy pacemakers and defibrillators and abandoned leads. Heart Rhythm. 2018;15:228–33. S8.2-31.	 Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or

dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346:1854–62.

Downloaded from http://ahajournals.org by on October 7, 2026